Studies have predicted the association of three IL-6 promoter polymorphisms (rs1800795, rs1800796, rs1800797) with increased risk of cervical cancer, colorectal cancer, breast cancer, prostate cancer, lung cancer, glioma, non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma [27–29]. This evidence concerns the gene IL6 and breast carcinoma.